| T22592 |
ATPγS tetralithium salt
|
93839-89-5
|
98%
|
|
|
ATPγS tetralithium salt is a substrate for nucleotide hydrolysis and RNA unraveling activity of the eukaryotic translation initiation factor eIF4A, associated wi...
|
| T61859 |
MK-28
|
864388-65-8
|
98%
|
|
|
MK-28 is a selective PERK agonist that reduces toxicity and prolongs survival in a Huntington's disease model.MK-28 has a significant killing effect on MK28 gast...
|
| T11374 |
GCN2-IN-6
|
2183470-09-7
|
95.04%
|
|
|
GCN2-IN-6 is also a eIF2α kinase PERK inhibitor with an IC50 of 0.26 nM (in enzymatic assay) and 230 nM (in cells). GCN2-IN-6 is a potent, and orally available ...
|
| T14044 |
4E2RCat
|
432499-63-3
|
96.48%
|
|
|
4E2RCat is an eIF4E-eIF4G interaction inhibitor (IC50: 13.5 μM).
|
| T29955 |
AMC-01
|
1047978-71-1
|
97.49%
|
|
|
AMC-01 has potential antiviral activity and induces dose- and time-dependent inactivation of eIF2-α via phosphorylation of serine residue 51. AMC-01 can be used ...
|
| T9149 |
2BAct
|
2143542-28-1
|
97.97%
|
|
|
2BAct is a novel eif2b activator, preventing neurological defects caused by a chronic integrated stress response
|
| T2027 |
ISRIB
|
548470-11-7
|
98%
|
|
|
ISRIB is a potent and selective PERK inhibitor.
|
| T2614 |
GSK2606414
|
1337531-36-8
|
98.04%
|
|
|
GSK2606414 is an oral-available and specific PERK inhibitor (IC50=0.4 nM).
|
| T38732 |
PERK-IN-4
|
1337531-89-1
|
98.14%
|
|
|
PERK-IN-4 is a potent and selective PERK inhibitor with an IC50 value of 0.3 nM.PERK-IN-4 can be used in the study of cancer and neurological disorders.
|
| T14902 |
CCT020312
|
324759-76-4
|
98.36%
|
|
|
CCT020312 is a selective activator of EIF2AK3 and PERK. CCT020312 durably inhibits cell proliferation and elicits the phosphorylation of EIF2A.
|
| TQ0131 |
Rocaglamide
|
84573-16-0
|
98.46%
|
|
|
Rocaglamide (Roc-A), isolated from the genus Aglaia, can be used to treat coughs, injuries, asthma, and inflammatory skin diseases. It is a potent inhibitor of N...
|
| T2417 |
Sal003
|
1164470-53-4
|
98.58%
|
|
|
Sal003, an effective cell-permeable analog, inhibitis the eIF2α phosphatase.
|
| T7150 |
BTdCPU
|
1257423-87-2
|
98.61%
|
|
|
BTdCPU is a potent activator of heme-regulated eIF2α kinase (HRI) . BTdCPU promotes eIF2α phosphorylation and induced apoptosis in resistant cell.
|
| T3564 |
SHP099
|
1801747-42-1
|
98.73%
|
|
|
SHP099 (SHP099 free base) free base is an effective, selective, orally bioavailable, and efficacious SHP2 inhibitor (IC50 =0.07 μM and p-ERK modulation in cells ...
|
| T6183 |
ISRIB (trans-isomer)
|
1597403-47-8
|
98.81%
|
|
|
ISRIB (trans-isomer) (ISRIB trans-isomer), the trans-isomer of ISRIB, is a effective and specific PERK inhibitor (IC50: 5 nM).
|
| T77499 |
MSU-42011
|
2456434-36-7
|
99.04%
|
|
|
MSU-42011 is an orally active retinoid X receptor-like (RXR) agonist.MSU-42011 potently inhibits the expression of iNOS, low SREBP-induced and activated RXR, and...
|
| T3207 |
Briciclib
|
865783-99-9
|
99.11%
|
|
|
Briciclib (ON 014185) is a small molecule that suppresses cyclin D1 accumulation in Y cells.
|
| T2665 |
4EGI-1
|
315706-13-9
|
99.12%
|
|
|
4EGI-1, a competitive eIF4E/eIF4 g interaction inhibitor, binds to eIF4E(KD=25 μM).
|
| T1742 |
4E1rcat
|
328998-25-0
|
99.36%
|
|
|
4E1RCat is a dual inhibitor of eIF4E:eIF4 g and eIF4E:4E-BP1 interaction. And it inhibits the binding of eIF4 g to eIF4E with IC50 of 3.2 μM.
|
| T73053 |
BAY 2965501
|
2732902-08-6
|
99.4%
|
|
|
BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor that induces pERK activation.BAY 2965501 can be used in the study of cancer.
|
